Microbiology

Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting

Retrieved on: 
Monday, March 11, 2024

SCOTTSDALE, Ariz., March 11, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, announces that data from the Phase 1 clinical trial (DFD-29-CD-006) assessing the impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on the microbial flora of healthy adults were presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting that took place March 8-12, 2024, in San Diego, CA. The clinical trial also assessed the safety and tolerability of the treatment. The data were presented by Srinivas Sidgiddi, M.D., Vice President, Research & Development of Journey Medical. DFD-29 is being developed for the treatment of rosacea in collaboration with Dr. Reddy’s Laboratories Ltd.

Key Points: 
  • The clinical trial also assessed the safety and tolerability of the treatment.
  • The data were presented by Srinivas Sidgiddi, M.D., Vice President, Research & Development of Journey Medical.
  • Microbiological samples were collected from the skin (forehead), stool and vagina at multiple timepoints through the study.
  • Additional information on the DFD-29 Phase 1 clinical trial can be found on ClinicalTrials.gov using the identifier NCT05597462 .

Rapid Micro Biosystems Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Guidance

Retrieved on: 
Friday, March 1, 2024

LOWELL, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced its financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Strong fourth quarter 2023 revenue growth of 45% compared to the fourth quarter of 2022.
  • Total cost of revenue was $6.5 million in the fourth quarter of 2023, compared to $7.0 million in the fourth quarter of 2022.
  • Total operating expenses decreased 18% to $12.0 million in the fourth quarter of 2023, compared to $14.7 million in the fourth quarter of 2022.
  • Net loss for the fourth quarter of 2023 was $11.2 million, compared to $16.4 million in the fourth quarter of 2022.

Bruker Announces Share Purchase Agreement to Acquire Molecular Diagnostics Innovator ELITechGroup

Retrieved on: 
Wednesday, February 28, 2024

This put option has now been exercised, and the parties have entered into a binding share purchase agreement.

Key Points: 
  • This put option has now been exercised, and the parties have entered into a binding share purchase agreement.
  • ELITechGroup, with over 500 employees and over 40 active patents, develops and commercializes innovative, proprietary molecular diagnostic (MDx) systems and assays, as well as niche biomedical systems and microbiology products.
  • Establishing this unique business within Bruker - a well-respected global life-science tools and specialty diagnostics company - provides an exciting opportunity to further grow our molecular diagnostics, microbiology and biomedical systems portfolios.
  • Upon closing, ELITech is expected to be a stand-alone business within Bruker’s Microbiology and Infection Diagnostics division, as a part of the Bruker CALID Group.

Seek Labs Welcomes Alison O’Mahony, PhD as new Vice President of Pharmaceutical Research

Retrieved on: 
Thursday, February 22, 2024

Seek Labs, a healthcare innovations company developing next-generation molecular diagnostic systems and novel gene therapies, announced today the appointment of Alison O’Mahony, PhD as Vice President of Pharmaceutical Development.

Key Points: 
  • Seek Labs, a healthcare innovations company developing next-generation molecular diagnostic systems and novel gene therapies, announced today the appointment of Alison O’Mahony, PhD as Vice President of Pharmaceutical Development.
  • With nearly 20 years of experience in R&D, phenotypic drug discovery, and assay and scientific operations, O’Mahony brings extensive knowledge and expertise to Seek Labs where she will spearhead the pharmaceutical research division, leading strategic initiatives to advance Seek Labs’ innovation in novel gene therapies.
  • "We are delighted to welcome Alison O’Mahony to Seek Labs as our new Vice President of Pharmaceutical Development," said Jared Bauer, CEO.
  • She also serves on professional boards including Talent Ready Utah, Breakthrough Cancer Research, and the Inflammation Research Association.

American Water Awarded New Research Grant Focusing on Early Warning System for Algal Blooms

Retrieved on: 
Wednesday, February 21, 2024

American Water (NYSE: AWK), the largest regulated water and wastewater utility company in the U.S., today announced that it has been awarded a new grant from The Water Research Foundation (WRF), Determining the Role of Spectral Imaging as an Early Warning System for Presence/Significance of Algal Blooms [5266].

Key Points: 
  • American Water (NYSE: AWK), the largest regulated water and wastewater utility company in the U.S., today announced that it has been awarded a new grant from The Water Research Foundation (WRF), Determining the Role of Spectral Imaging as an Early Warning System for Presence/Significance of Algal Blooms [5266].
  • This research aims to develop cost-effective tools for early and reliable identification of harmful algal blooms.
  • “American Water is delighted to partner with The Water Research Foundation on this important water-related research, and continue to advance the science of drinking water,” said Lynda DiMenna, Chief Environmental Officer, American Water.
  • “Research into algal blooms is a critical component in continuing to provide clean, safe and reliable water services to customers and across the water industry.”
    Algal blooms can have negative impacts on both water providers and communities, affecting operations as well as public health.

NanoMosaic launches AAV gene therapy bioprocessing and manufacturing QC assays for simultaneous capsid & transgene interrogation with high standardization

Retrieved on: 
Wednesday, March 6, 2024

The assays are seamlessly deployable across upstream and downstream stages of the gene therapy workflow, while harmonizing the data from bioprocessing to batch release QC.

Key Points: 
  • The assays are seamlessly deployable across upstream and downstream stages of the gene therapy workflow, while harmonizing the data from bioprocessing to batch release QC.
  • "The objectives pursued by NanoMosaic are positive steps forward for a space desperate for a fit-for-purpose tool that can be standardized throughout the entire gene therapy development and manufacturing processes.
  • "NanoMosaic is excited to offer a unique solution to a challenging and fast-growing gene therapy market," said Qimin Quan, PhD, co-founder and Chief Scientific Officer.
  • NanoMosaic will feature the platform and unique gene therapy applications in a live broadcast scientific webinar alongside industry leaders on March 26, 2024, hosted by Genetic Engineering News (GEN).

SciBase Partners with Skinobs to Offer Nevisense on Global Cosmetic Testing Platform

Retrieved on: 
Wednesday, February 28, 2024

Through this partnership, SciBase will now offer Nevisense for assessing skin barrier function within cosmetic testing on the Skinobs platform.

Key Points: 
  • Through this partnership, SciBase will now offer Nevisense for assessing skin barrier function within cosmetic testing on the Skinobs platform.
  • Through the Skinobs platform, researchers can easily find information on who is conducting what tests in the field of dermocosmetic, nutraceutical, and active ingredient testing.
  • The cosmetic testing market segment represents a significant potential addressable customer base for SciBase and is expected to grow exponentially into 2030.
  • "SciBase is already involved in discussions with several large cosmetic companies who wish to use Nevisense in their research and development.

BayCare Names Three to Vice President Roles; Creates New Surgical Services Vice President Position

Retrieved on: 
Thursday, February 22, 2024

The health system has also created a new vice president of perioperative services position to lead surgical services initiatives across BayCare's 16 hospitals.

Key Points: 
  • The health system has also created a new vice president of perioperative services position to lead surgical services initiatives across BayCare's 16 hospitals.
  • "It is my privilege to announce the naming of three long-time BayCare team members to vice president roles," said BayCare's Chief Team Resources Officer Kyle Barr.
  • Angel Brown has been promoted to vice president of talent acquisition and inclusion.
  • BayCare has announced plans to build a 17th hospital in Manatee County, where it already has doctor's offices, and it delivers home care services across 13 counties.

Town of Trenton fined $100,000 for violating the Fisheries Act in Nova Scotia

Retrieved on: 
Friday, February 16, 2024

On February 15, 2024, the Town of Trenton was ordered to pay a total of $100,000, after pleading guilty to one count of violating the Fisheries Act at the Provincial Court of Nova Scotia in Pictou County.

Key Points: 
  • On February 15, 2024, the Town of Trenton was ordered to pay a total of $100,000, after pleading guilty to one count of violating the Fisheries Act at the Provincial Court of Nova Scotia in Pictou County.
  • Some of the conditions include: training on the Fisheries Act and its requirements; training on proper effluent sampling protocols for Town of Trenton employees and contractors; completing routine sampling; and publishing emergency contact information and information about the incident and sentencing on the Town of Trenton website.
  • On November 13, 2019, Environment and Climate Change Canada enforcement officers received a complaint of a strong sewage smell around Lowden Brook along North Main Street in Trenton, Nova Scotia.
  • Environment and Climate Change Canada administers and enforces the pollution prevention provisions of the Fisheries Act.

Leading Intellectual Property Law Firm Fish & Richardson Launches Team Focused on Protecting Life Sciences Innovations

Retrieved on: 
Monday, February 12, 2024

Fish & Richardson has appointed leading trial attorney Martina Hufnal and veteran patent prosecutor Todd Garcia , Ph.D. to chair the firm’s Life Sciences Industry Team.

Key Points: 
  • Fish & Richardson has appointed leading trial attorney Martina Hufnal and veteran patent prosecutor Todd Garcia , Ph.D. to chair the firm’s Life Sciences Industry Team.
  • The team represents every sector of the life sciences market, including pharmaceutical, medical device, medtech and biotech companies, as well as academic and research institutions.
  • "Fish has a nationally recognized bench of trial attorneys and IP practitioners whose experience representing life sciences companies is second to none,” said Fish President and CEO John Adkisson .
  • Fish attorneys are experienced in each sector of the life sciences market, including small molecule, large molecule, medical device, medtech, and biotech.